scholarly journals Possible opioid‐saving effect of cannabis‐based medicine using individual‐based data from the Norwegian Prescription Database

Author(s):  
Jørgen G. Bramness ◽  
Vidar Hjellvik ◽  
Audun Stubhaug ◽  
Svetlana Skurtveit

2018 ◽  
Vol 37 (4) ◽  
pp. 1448-1457 ◽  
Author(s):  
Siri A. Mauseth ◽  
Svetlana Skurtveit ◽  
Eva Skovlund ◽  
Arnulf Langhammer ◽  
Olav Spigset


2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Guttorm Raknes ◽  
Lars Småbrekke

Abstract In this controlled before-after study based on data from the Norwegian Prescription Database, we examine whether starting off-label use of Low Dose Naltrexone (LDN) is followed by changes in the consumption of psychotropic medicines including antiepileptics. Patients that collected LDN for the first time in 2013 (N = 11247) were included and stratified into three groups based on LDN exposure. We compared differences in means of cumulative number of defined daily doses (DDD) as well as changes in the number of users one year before and one year after starting LDN. There was a dose-response association between increasing LDN exposure and reductions in the number of users of antiepileptics, antipsychotics and antidepressants. There were significant difference-in-differences in DDDs between the groups with the lowest and highest LDN exposure of antipsychotics (1.4 DDD, 95% CI 0.4 to 2.3, p = 0.007), and in number of users of antiepileptics (3.1% points, 95% CI 1.6% to 4.6%, p < 0.001), antipsychotics (2.1% points, 95% CI 1.2% to 3%, p < 0.001), and antidepressants (2.8% points, 95% CI 1.1% to 4.4%, p = 0.001). The findings show an association between the initiation of persistent LDN use and reduced consumption of several psychotropic medicines and antiepileptics. Beneficial effects of LDN in the treatment of psychiatric diseases cannot be ruled out.



2019 ◽  
Vol 177 (1) ◽  
pp. 185-195 ◽  
Author(s):  
Thomas Helland ◽  
Kari Britt Hagen ◽  
Martha Eimstad Haugstøyl ◽  
Jan Terje Kvaløy ◽  
Siri Lunde ◽  
...  


2019 ◽  
Vol 48 (5) ◽  
pp. 559-566
Author(s):  
Adelheid-Charlotte Wærholm ◽  
Eivind Meland ◽  
Reidun L. S. Kjome

Aim: To examine whether subjective well-being (SW) and body concern among adolescents aged 15–19 years has an impact on adult health, measured by medications dispensed on average 18 years later. Methods: Data collected in the Nord-Trøndelag Health Study (HUNT) was paired with data from the Norwegian Prescription database (NorPD). We investigated the effects of adolescent SW and body concern on total number of medications, on use of anti-infectives (ATC-group J), medication for the musculo-skeletal system (ATC-group M), anxiolytics, hypnotics and sedatives (ATC-groups N05B and N05C), and finally antipsychotics, antidepressants and psychostimulants, agents used for attention-deficit/hyperactivity disorder and nootropics (ATC-groups N05A, N06A and N06B). We used multi-variable models where we entered body dissatisfaction and SW simultaneously in the models in order to adjust for the associations between the predictors, and also adjusted for possible confounders in the models. Results: Both body concern (dieting and dieting desire) and impaired SW predicted drug use 17–18 years after the participants were surveyed in adolescence. The impact was disease specific as body concern was the most influential predictor for drugs used for somatic diseases and complaints, whereas impaired SW was more strongly associated with drug use for mental health diseases and complaints. Conclusions: SW and body concern are important health determinants in the transition between adolescence and adulthood.



2018 ◽  
Vol 4 ◽  
pp. 144-152 ◽  
Author(s):  
Tina Lokke Vie ◽  
Karl Ove Hufthammer ◽  
Turid Lingaas Holmen ◽  
Eivind Meland ◽  
Hans Johan Breidablik




Sign in / Sign up

Export Citation Format

Share Document